Veterans and their families are suffering, the Veterans Health Administration (VHA) is overwhelmed, and the established treatments for Post-Traumatic Stress related disorders (PTSD) are not sufficiently effective.
To address this problem Veterans for Compassionate Care is working with Patients Out of Time, Enigami Medical Cannabis, LLC and other Supporters to conduct a National, Community based Study.
Join the Veterans PTSD Study
About the PTSD Study
The study attempts to answer the question, "Do U.S. Veterans, who are diagnosed with Post Traumatic Stress, benefit from the use of Medical Cannabis as a treatment modality?" If the information is sufficient to determine whether Medical Cannabis is of benefit, is a detriment, or is of negligible value it may be possible to become more granular in the determination of which specific cannabinoid combinations are related to the symptoms specific to the diagnosis of Post-Traumatic Stress Disorder (PTSD).
The criteria for PTSD are strictly taken from the DSM V with no variance. The study will not provide Medical Cannabis nor treatment. The Medical Cannabis used by the study participants will be subject to current standardized testing and labeling of medical cannabis products and is commercially available. The study participants will be chosen from states which currently authorize medical cannabis and participants will be registrants of those states. The technology employed for the study may accommodate 10,000 (plus) participants.
There are several participant status' which will prevent a potential candidate from participating in the study: being pregnant, using cannabis and breastfeeding, planning on becoming pregnant, NOT being a US Veteran, NOT being authorized to use Medical Cannabis, being in violation of their state's Medical Marijuana Registry regulations, or NOT meeting the diagnostic criteria for PTSD.
The technology being donated ("licensed") to the study is strongly protected by a number of pending patents and trademarks. Enigami Systems, Inc. is the owner of the intellectual property ("patents" and "trademarks"), and the decision to donate the services of the technology is authorized by Enigami Systems, Inc. through it's subsidiary, Enigami Medical Cannabis, LLC. Use of the technology by the study does not construe ownership of the technology by the study but remains the exclusive domain, with all rights preserved, of Enigami Systems, Inc.
Essentially the online "service", or survey, donated by Enigami Systems, Inc., through it's subsidiary is characterized as:
"Only the absolute minimum of personally identifying information for a personal health record. A Patient registers, then designates PTSD as the condition he/she wishes to track. The study participant then decides how often they want email notices sent to them to remind them to record their symptom status and medication ("Over the Counter", "mainstream medications", and/or Medical Cannabis), and they occasionally log the information. This information is translated into an easy to read graph showing treatment progress. These personal health records are HIPAA compliant (A HIPAA review and "penetration test" has been performed on the stand alone database application). HIPAA Privacy Rules are the national standards to protect individual's privacy. We have taken additional, more advanced, security measures, however, which are noted on the website e security notices. The highest degree of encryption has been utilized. Study participation will be offered, pro bono, to the participants for eighteen (18) months."
The study/survey will seek to answer the question of whether Medical Cannabis is a benefit, a detriment, or is of negligible value in a treatment modality. Data points include (but may not be inclusive of): gender, age, military Veteran status, state of residence (and authorization to use Medical Cannabis), non-pregnancy/breast feeding status, name of medication (generic or otherwise), dosage of medication, schedule of medication, symptom status, on-going symptom status, symptom status in relation to the medications, treatment application, "side effects" (via patient journaling/narrative), the specific cannabinoid combinations ("%") of the Medical Cannabis products.